Physician profile
Ingrid Hall
NPI 1235363490
$3,266.77
in general payments reported to CMS, 2019-2025
26 companies · $570 in 2025
The $570 reported for 2025 was less than what a typical Rheumatology provider received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $867 · 2020: $136 · 2021: $373 · 2022: $507 · 2023: $335 · 2024: $479 · 2025: $570.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,384.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,383.65 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $546.45 | 2019-2025 | Tremfya |
| Pfizer INC. | $453.49 | 2019-2024 | |
| Amgen INC. | $365.12 | 2019-2025 | Enbrel, Otezla, Tavneos |
| Ucb, INC. | $321.25 | 2019-2025 | Cimzia, Bimzelx |
| Abbvie INC. | $315.74 | 2019-2025 | Rinvoq |
| Novartis Pharmaceuticals Corporation | $280.03 | 2019-2025 | |
| Glaxosmithkline, LLC. | $183.03 | 2019-2025 | Benlysta |
| Lilly USA, LLC | $111.25 | 2021-2025 | Taltz |
| Boehringer Ingelheim Pharmaceuticals, INC. | $64.71 | 2021-2024 | Ofev |
| Ani Pharmaceuticals, INC. | $64.62 | 2025 | Purified Cortrophin Gel |
| E.R. Squibb & Sons, L.L.C. | $58.94 | 2019-2022 | |
| Genentech USA, INC. | $58.74 | 2019-2025 | Actemra |
| Sobi, INC | $57.42 | 2019-2023 | |
| Fidia Pharma USA INC. | $47.08 | 2020-2023 | Triluron, Hymovis |
| Actelion Pharmaceuticals US, INC. | $45.59 | 2019-2022 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ultragenyx Pharmaceutical INC. | $44.27 | 2021-2022 | |
| Astrazeneca Pharmaceuticals LP | $42.32 | 2022-2025 | Saphnelo |
| Regeneron Healthcare Solutions, INC. | $38.39 | 2019 | |
| Horizon Therapeutics Plc | $36.63 | 2019 | |
| Radius Health, INC. | $28.27 | 2019 | |
| Genzyme Corporation | $21.57 | 2022 | |
| Alexion Pharmaceuticals, INC. | $20.63 | 2019 | |
| Bioventus LLC | $17.27 | 2020 | |
| Novo Nordisk INC | $15.87 | 2019 | |
| Pacira Therapeutics, INC. | $14.28 | 2019 | |
| Celgene Corporation | $13.81 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ingrid Hall listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.